- Home
- ABEO vs NLSP Comparison
ABEO vs NLSP Comparison
Compare ABEO & NLSP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ABEO
- NLSP
- Stock Information
- Founded
- ABEO N/A
- NLSP 2015
- Country
- ABEO United States
- NLSP Switzerland
- Employees
- ABEO N/A
- NLSP N/A
- Industry
- ABEO Biotechnology: Pharmaceutical Preparations
- NLSP Biotechnology: Pharmaceutical Preparations
- Sector
- ABEO Health Care
- NLSP Health Care
- Exchange
- ABEO Nasdaq
- NLSP Nasdaq
- Market Cap
- ABEO 243.9M
- NLSP 243.8M
- IPO Year
- ABEO 1980
- NLSP 2021
- Fundamental
- Price
- ABEO $6.54
- NLSP $5.06
- Analyst Decision
- ABEO Strong Buy
- NLSP
- Analyst Count
- ABEO 3
- NLSP 0
- Target Price
- ABEO $18.00
- NLSP N/A
- AVG Volume (30 Days)
- ABEO 254.3K
- NLSP 26.6K
- Earning Date
- ABEO 11-11-2024
- NLSP 10-18-2024
- Dividend Yield
- ABEO N/A
- NLSP N/A
- EPS Growth
- ABEO N/A
- NLSP N/A
- EPS
- ABEO N/A
- NLSP N/A
- Revenue
- ABEO N/A
- NLSP N/A
- Revenue This Year
- ABEO N/A
- NLSP N/A
- Revenue Next Year
- ABEO $7,097.06
- NLSP N/A
- P/E Ratio
- ABEO N/A
- NLSP N/A
- Revenue Growth
- ABEO 147.52
- NLSP N/A
- 52 Week Low
- ABEO $3.05
- NLSP $4.08
- 52 Week High
- ABEO $9.01
- NLSP $40.60
- Technical
- Relative Strength Index (RSI)
- ABEO 68.61
- NLSP 41.04
- Support Level
- ABEO $6.06
- NLSP $4.72
- Resistance Level
- ABEO $6.48
- NLSP $5.50
- Average True Range (ATR)
- ABEO 0.33
- NLSP 0.64
- MACD
- ABEO 0.05
- NLSP 0.03
- Stochastic Oscillator
- ABEO 85.38
- NLSP 34.17
About ABEO Abeona Therapeutics Inc.
Abeona Therapeutics Inc is a clinical-stage biopharmaceutical company. The firm is focused on developing gene therapies and plasma-based products for life-threatening rare genetic diseases. Its clinical programs consist of pz-cel, an autologous, engineered cell therapy currently in development for recessive dystrophic epidermolysis bullosa (RDEB). The Company's development portfolio also features adeno-associated virus (AAV)-based gene therapies designed to treat unmet, medically needed ophthalmic diseases using the novel AIM.
About NLSP NLS Pharmaceutics Ltd.
NLS Pharmaceutics Ltd is a biopharmaceutical company. It is engaged in the discovery and development of life-improving drug therapies to treat rare and complex CNS disorders. It focuses on developing therapeutics for the treatment of neurobehavioral and neurocognitive disorders. The company's tangible assets are held in the United States. Its lead products are Quilience, to treat narcolepsy and Nolazol, to treat ADHD.